Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Given poor outcomes, strategies to improve ventricular assist devices (VADs) for single-ventricle patients with bidirectional Glenn (BDG) palliation are needed.
Methods: This retrospective review describes an institutional experience with VAD support for patients with BDG from April 2011 to January 2019. Surgical strategies, complications, and causes of death are described. Survival to heart transplantation for various strategies are compared.
Results: A total of 7 patients with BDG (weights, 5.6 to 28.8 kg; ages, 7 months to 11 years) underwent VAD implantation. Three patients underwent implantation of Berlin Heart EXCOR devices (Berlin Heart, Inc, Spring, TX), 2 had HeartWare HVADs (Medtronic, Minneapolis, MN) implanted, and 2 patients underwent implantation of paracorporeal continuous flow devices. Four patients underwent ventricular inflow cannulation, and 3 underwent atrial inflow cannulation. At the time of VAD implantation, the BDG was left intact in 3 patients, taken down in 3 patients, and created de novo in 1 patient. Over a total of 420 VAD support days, 2 patients survived to heart transplantation, 1 patient with HeartWare ventricular cannulation and intact BDG (after 174 days) and another with Berlin Heart atrial cannulation and BDG take-down (after 72 days). There were 3 deaths within 2 weeks of VAD implantation (2 from respiratory failure, 1 from infection) and 2 deaths after 30 days as a result of strokes.
Conclusions: The surgical strategy and postoperative management of VAD with BDG are still evolving. Successful support can be achieved with (1) both pulsatile and continuous flow pumps, (2) atrial or ventricular cannulation, and (3) with or without BDG take-down. Surgical strategy should be determined by individual patient anatomy, physiology, and condition.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.athoracsur.2019.12.088 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinician Perspectives on Compassionate Deactivation of Pediatric Ventricular Assist Devices.
ASAIO J
August 2025
Anesthesiology, Perioperative and Pain Medicine, Stanford School of Medicine, Stanford Medicine Children's Health, Palo Alto, California.
Following ventricular assist device (VAD) placement, families and clinicians often have differing perspectives. When adverse events reduce patients' quality of life, families and clinicians question the desirability of continuing VAD support. Given the increasing use of VAD in pediatrics, pediatric-specific guidelines for the process of compassionate deactivation (CD) of VAD are needed, based in part on the perspectives of pediatric heart failure clinicians.
View Article and Find Full Text PDFVericiguat Use in Right Heart Failure Management Following Left Ventricular Assist Device Implantation: A Case Report.
ASAIO J
August 2025
From the Department of Transplant Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.
Right heart failure (RHF) is a major cause of mortality in patients using left ventricular assist devices (LVADs). Vericiguat, an oral soluble guanylate cyclase stimulator, has recently been used to treat chronic heart failure (HF) with a reduced ejection fraction (EF) and is expected to improve RHF owing to its pulmonary vasodilatory and inotropic properties in patients with an LVAD. A 62 year old woman with advanced HF due to cardiac sarcoidosis was transferred to our center with HF recurrence and left ventricular (LV) thrombosis.
View Article and Find Full Text PDFLeft Ventricular Assist Device Implantation and Heart Transplantation in a Young Man With Duchenne Muscular Dystrophy.
Pediatr Transplant
September 2025
Department of Pediatrics (Cardiology), Stanford University School of Medicine, Palo Alto, California, USA.
Background: With advances in respiratory care allowing for improved survival, cardiomyopathy has emerged as the leading cause of death in patients with Duchenne Muscular Dystrophy (DMD). As end-stage heart failure emerges as the primary life-limiting complication in DMD patients, their consideration for advanced heart failure therapies, including ventricular assist devices (VADs) and/or heart transplantation (HT), is increasing. To date, however, there are few published reports of HT in DMD patients.
View Article and Find Full Text PDFLiving myocardial slices retain patient-specific features: Insights into etiology and therapeutic history.
JHLT Open
August 2025
Department of Cardiology and Experimental Cardiology Laboratory, Division of Heart & Lungs, University Medical Centre Utrecht, Utrecht, the Netherlands.
Background: Living myocardial slices (LMS) are an emerging translational model for studying myocardial function, disease mechanisms, and therapeutics. However, the extent to which findings correlate with clinical characteristics is unknown. This study aimed to evaluate whether LMS retain patient-specific functional and pathological characteristics, reflecting diverse etiologies, pharmacological regimens, and clinical interventions.
View Article and Find Full Text PDFEchocardiographic Imaging Considerations for Post-Implant Evaluation of the Transcatheter EVOQUE Tricuspid Valve Replacement System.
JACC Cardiovasc Imaging
July 2025
Baylor Scott and White Cardiovascular Imaging Core Laboratory, Baylor Scott and White-The Heart Hospital, Plano, Texas, USA.
The transcatheter EVOQUE tricuspid valve replacement system is an approved device for the treatment of patients with symptomatic severe tricuspid regurgitation despite medical therapy both in the United States and in Europe. Specific imaging requirements are needed in the screening and in the intraprocedural phase as well as to assess this valve after implantation, in order to assess its positioning and performance. In this review, focus will be on the postoperative echocardiographic assessment of device positioning and stability; evaluation of residual central tricuspid regurgitation or paravalvular leak; valve thrombosis/degeneration; interaction of the device frame with the right ventricle and adjacent structures, including the aortic valve and interventricular septum; and placement of pacemaker leads.
View Article and Find Full Text PDF